Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that new data from across the companies’ inflammatory disease research and development program will be presented at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting in Atlanta from November 8-13. The companies will present 20 abstracts at this year’s meeting, including key data on the investigational medicine filgotinib in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), as well as real-world RA treatment outcomes and care.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191031005841/en/
“These latest data add to the growing body of evidence on the potential role of filgotinib in the management of rheumatoid arthritis and other inflammatory diseases,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. “People living with RA may experience long-term symptoms that persist despite currently available treatment options. At Gilead, we are working to help improve the lives of people living with inflammatory conditions and look forward to sharing these latest data at ACR/ARP.”
“We are proud to share these latest data at the 2019 ACR/ARP Annual Meeting,” said Dr. Walid Abi-Saab, Chief Medical Officer, Galapagos. “These results continue to show the potential for filgotinib in RA for patients who face significant challenges living with this disease. Further, we are particularly excited to embark on the PENGUIN Phase 3 trials in psoriatic arthritis, as filgotinib has the potential to address the important unmet medical need of patients living with this disease.”
New Filgotinib Efficacy and Safety Data in Rheumatoid Arthritis
Key presentations include multiple subgroup analyses from the FINCH 2 clinical trial that demonstrate the potential of filgotinib across specific RA populations who have experienced an inadequate response to biologic disease-modifying anti-rheumatic drugs (bDMARDs), including those in this difficult-to-treat population with anemia, thrombocytopenia and leukopenia. Key data will also include pooled safety results from the Phase 3 FINCH program (NCT02889796, NCT02873936, NCT02886728), and safety outcomes from the long-term DARWIN-3 trial (NCT02065700).
- A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis (Poster, #504, Sunday, Nov. 10; 9:00am)
- A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs (Poster, #517, Sunday, Nov. 10; 9:00am)
- Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biologic DMARDs (Oral, #2875, Wednesday, Nov. 13; 9:00am)
- Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis (Poster, #1329, Monday, Nov. 11; 9:00am)
- Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study (Poster, #550, Sunday, Nov. 10; 9:00am)
In RA, biomarker research seeks to better characterize the molecular basis of the disease and identify populations that may benefit most from a treatment. Gilead is committed to helping drive forward this emerging area of innovation. Presented data will assess the relationship between a series of RA biomarkers and the therapeutic response of filgotinib.
- bDMARD-Experienced Filgotinib-Treated Patient Samples Exhibit a Partial Reversion to the Peripheral Molecular Profile of a Demographically Matched Healthy Population (Poster, #45, Sunday, Nov. 10; 9:00am)
- Key Inflammatory Biomarkers at Baseline are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs (Poster, #46, Sunday, Nov. 10; 9:00am)
- A Composite IFN-Based Signature is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients (Poster, #2012, Tuesday, Nov. 12; 9:00am)
Real-World Treatment Experiences in Rheumatoid Arthritis
In addition to therapeutic innovation, increased understanding of the real-world experiences of patients living with RA is needed. Select data will highlight results from multiple studies focused on the overall burden of RA within the U.S.
- Treatment Patterns and Persistency Following First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012-2016 U.S. Medicare data (Oral, #953, Sunday, Nov. 10; 4:30pm)
- Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the U.S. (Poster, #204, Sunday, Nov. 10; 9:00am)
- Real-World Evidence: Infections Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the U.S. (Poster, #1374, Monday, Nov. 11; 9:00am)
Filgotinib in Psoriatic Arthritis
Long-Term Safety with Filgotinib in PsA
It is important to understand the safety profile as well as the durability of response to new therapeutic options across potential indications. Results from a long-term safety analysis evaluating the safety of filgotinib for people with PsA will be presented.
- Long-Term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study (Poster, #1534, Monday, Nov. 11; 9:00am)
Initiation of PENGUIN Phase 3 Program with Filgotinib in PsA
The efficacy and safety of 100 mg and 200 mg filgotinib once-daily compared to placebo will now be further investigated in the PENGUIN Phase 3 program. PENGUIN 1 (NCT04115748) will compare the efficacy and safety of filgotinib, adalimumab and placebo in approximately 1000 patients with active PsA who are naive to bDMARD therapy. PENGUIN 2 (NCT04115839) will measure efficacy and safety of filgotinib vs placebo in 390 patients with active PsA who have an inadequate response or are intolerant to bDMARD therapy. The primary endpoint of each trial is ACR20 response at week 12, with multiple secondary endpoints on signs and symptoms of PsA up to week 24 in PENGUIN 1, and week 16 in PENGUIN 2.
Filgotinib is an investigational agent and is not approved by the U.S. Food and Drug Administration or any other regulatory authority. Its efficacy and safety have not been established.
For more information, including a complete list of the abstracts being presented at the 2019 ACR/ARP annual meeting, please visit: https://acrabstracts.org.
For information about clinical trials with filgotinib, please visit: www.clinicaltrials.gov.
About the Filgotinib Collaboration
Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. The FINCH studies in rheumatoid arthritis are among several clinical trials of filgotinib in inflammatory diseases, which also include the EQUATOR Phase 2 program in psoriatic arthritis, the TORTUGA study in ankylosing spondylitis, the DIVERSITY Phase 3 trial (NCT02914561) in Crohn’s disease (also small bowel and fistulizing Crohn’s disease Phase 2 studies), the Phase 3 SELECTION trial (NCT02914522) in ulcerative colitis and the Phase 3 PENGUIN trial in psoriatic arthritis.
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Galapagos’ pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. The Company’s ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Galapagos Forward-Looking Statement
This release may contain forward-looking statements with respect to Galapagos, including statements regarding Galapagos' strategic ambitions, the mechanism of action and potential safety and efficacy of filgotinib, the anticipated timing of clinical studies with filgotinib and the progression and results of such studies. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of filgotinib due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties (including its collaboration partner for filgotinib, Gilead), and estimating the commercial potential of filgotinib. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on Form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
Gilead Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from ongoing and additional clinical trials involving filgotinib and the possibility that we are unable to complete one or more of such trials on the currently anticipated timelines. Further, it is possible that the parties may make a strategic decision to discontinue development of filgotinib, and as a result, filgotinib may never be successfully commercialized. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Greg Mann, Investors
Arran Attridge, Media
Elizabeth Goodwin, Investors
Carmen Vroonen, Media
+32 473 824 874
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PTW International Announces Orange Rock Studios, Their Product and Game Development Arm11.12.2019 20:00:00 EET | Press release
Pole to Win International, Ltd. (PTW), the industry-leading video games and tech services outsourcer, today announced the launch of its product and game development arm, Orange Rock Studios. Orange Rock Studios will enhance the service offering of PTW, a gaming industry stalwart with an established and diverse dossier of top-tier clients across multiple verticals. “The time to be disruptive is now,” said Deborah Kirkham, CEO of PTW. “At Orange Rock, we foster future technologies to anchor projects with ingenuity and discipline for generation Y and Z. Together with our clients, we envision and engineer digital experiences.” “Orange Rock is the engine that will build PTW’s future by enabling us to bring each of our existing service lines - Quality Assurance, Customer Support, Audio Production, Localization, and Translation - to the forefront of their fields through cutting edge in-house tool development. We will deliver the creative products that accelerate our industry’s progress toward
Fastly Shares the Most Notable Internet Infrastructure Milestones of 2019, and What 2020 Might Bring for the Expansion of Platform-Independent Computing11.12.2019 19:30:00 EET | Press release
Fastly, Inc. (NYSE: FSLY), provider of a global edge cloud platform, today released its “Behind the Screens” retrospective detailing 2019’s notable milestones in internet infrastructure, from the increased adoption of modernized protocols, to the growth in reach and capacity of global high-speed internet, and more. Fastly’s CTO and co-founder, Tyler McMullen, anticipates that these advancements, combined with the rise of WebAssembly and the extension of code portability across platforms and devices, set the programming world up for achieving broader value from serverless computing. The State of Internet Infrastructure in 2019 This year saw a groundswell of grassroots protocol improvements, sweeping shifts toward encryption due to increased focus on data privacy, and a preview into WebAssembly’s possibilities at the edge, as well as: New satellites that took to the sky and submarine cables that were installed to grow capacity around the globe. Congestion control reimagined through BBR,
Invicro Supports the Alzheimer’s Disease Neuroimaging Initiative11.12.2019 18:37:00 EET | Press release
Invicro LLC, a Konica Minolta Company, today announced funding support for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and two of their distinguished scientists within the Alzheimer’s biomarkers space, Drs. Roger Gunn and Kenneth Marek, will join the ADNI-Private Partner Scientific Board (PPSB). Invicro is a global provider of imaging biomarkers, core lab services, advanced analytics and software solutions for drug discovery and development. ADNI is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). ADNI’s mission strives to detect AD at the earliest stage possible (pre-dementia) and identify ways to track the disease’s progression with biomarkers, as well as support advances in AD intervention, prevention, and treatment. “Invicro is delighted to support ADNI which plays a central role in the development of biomarkers that enable advances in AD interven
Sevan Elevate Brings Safety and Sustainability to New Heights11.12.2019 17:00:00 EET | Press release
Sevan Multi-Site Solutions, Inc. (Sevan), a global leader in data analytics, surveys, design, program management and construction services, is excited to announce the launch of Sevan Elevate, a program that will reinforce and continuously improve Safety and Sustainability across the company to deliver excellence to people and clients. Safety and Sustainability have been a strategic imperative since 2011 when Sevan was founded by a handful of entrepreneurs, including President and CEO Jim Evans. “Sevan’s tenets are Safety and Sustainability—both of which are woven through every element of the company. It is imperative that all our people—including team members, clients and business partners—return home safely to their loved ones at the end of the day,” Evans said. “With Sevan Elevate, the company is more committed than ever to raise awareness and compliance of Safety and Sustainability throughout the multi-site construction world. We’re not going to change the world overnight, but we ca
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma11.12.2019 16:30:00 EET | Press release
Kite, a Gilead Company (Nasdaq: GILD), and Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”) announced today that the companies have entered into a clinical collaboration to conduct a Phase 2, multicenter study of mavrilimumab, an investigational fully human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma. The objective of the study is to determine the effect of mavrilimumab on the safety of Yescarta. Kite will be the sponsor of this study and will be responsible for its conduct. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191211005149/en/ “We were excited to present data from several abstracts at the recent ASH meeting that build upon our understanding of the efficacy and safety profile of Yescarta and we are committed to the exploration
Lightbits Labs Launches Industry’s First NVMe/TCP Clustered Storage Solution11.12.2019 16:00:00 EET | Press release
Lightbits Labs, the leader in NVMe™ over TCP (NVMe/TCP) software-defined disaggregated storage, today has advanced its software solution, LightOS, to deliver the first NVMe/TCP clustered storage solution. With more companies moving away from direct attached storage (DAS), and with storage requirements typically growing far faster than compute requirements, both public-cloud providers and private-cloud builders are looking for ways to separate storage and compute so each can scale separately. One of the limiting factors to scaling disaggregated storage, however, is the need for high availability across clusters of storage and compute. Lightbits LightOS delivers the availability, flexibility and efficiency of hyperscale cloud infrastructure to on-premise data centers. LightOS is now the first NVMe/TCP storage solution that protects against data loss and avoids service interruptions at scale. In the presence of server, storage, or network failures, LightOS maximizes operational efficiency
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom